Doryx 2019 U.S. PROMOTIONAL AUDIT REPORT
- July 2020 •
- 19 pages •
- Report ID: 5210280 •
- Format: PDF
• How many physicians were reached by Doryx through reportable promotional activity in 2019 and how does this compare to its peer set in the Acne market?
• What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
• How does Mayne’s depth of coverage vary within key specialties (e.g., Dermatology and Infectious Disease) and how does this compare to its peers and the overall set of rep-accessible physicians?
• How often are physicians receiving paid meals for Doryx throughout the year (e.g., monthly, quarterly, annually)?
• Who were the most frequent meal recipients and top paid speakers for Doryx in 2019?
Data Sources and Methodology:
• MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, over 5 years of longitudinal data is available – covering payments to more than 1,000,000 U.S. healthcare professionals.
• Over 14,900 paid interactions across 3,100 physicians made on behalf of Doryx were carefully examined to support our analysis. In addition, interaction data from 12 peer products (e.g. Absorica, Aczone, Altreno, Avar, Clindacin, Epiduo, Minolira, Onexton, Retin, Seysara, Targadox, and Veltin ) was leveraged to provide benchmarking and market insights.